News

AVANT BIO Leads $7M Round in Intrepid Labs to Accelerate a New Era of Drug Formulation

AVANT BIO is proud to announce our lead investment in Intrepid Labs, a Toronto-based biotechnology company pioneering the use of AI and robotics to transform how drugs are formulated. The $7 million USD round, which brings Intrepid’s total funding to over $11 million, will support the expansion of its team, scaling of commercial operations, and continued development of its proprietary Valiant™ platform.

“Intrepid Labs is unlocking a new era in drug formulation, in which delivery format, dosing frequency, and patient experience can be intentionally designed from day one,” said Sebastien Latapie, Partner at AVANT BIO. “By enabling a more intelligent and data-driven approach, Intrepid has the potential to reshape how therapies are brought to market – faster, better, and more affordably.”

Since emerging from the University of Toronto in 2023, Intrepid has already partnered with several top-tier pharmaceutical companies, CROs, and CDMOs, while also advancing its own internal pipeline of long-acting and oral delivery technologies. Led by CEO and co-founder Dr. Christine Allen, the company brings together deep expertise in formulation science, automation, and AI to address one of the most persistent, and solvable challenges in drug development.

Visit the press release